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Abstract
Background Guidelines recommend treating actinic keratoses (AKs) as they are recognized as precursors of invasive
squamous cell carcinoma.
Objective The objective of this study was to collect real-world clinical data on the use of methyl aminolevulinate day-
light photodynamic therapy (MAL DL-PDT) for the treatment of face and scalp AK in Europe.
Methods A prospective, multicenter, non-interventional study was conducted in six European countries in patients
receiving a single treatment of MAL DL-PDT for face and/or scalp AK. Patient-reported outcomes were assessed by
patient questionnaires at baseline and at 3 months after treatment, efﬁcacy was assessed at 3 months using a 6-point
global improvement scale, and adverse events (AE) were recorded at each visit.
Results Overall, 325 patientswere enrolled from52 investigational centres, 314 ofwhomattended the 3-month visit.Most patients
had multiple lesions (58.4% had >10 lesions) with lesions mainly located on the scalp (60.0%) and/or forehead (54.2%). AKs were
predominantly grade I (39.4%) or grade II (33.2%), and 10.5%of patients had grade III lesions. The proportions of patients and physi-
cians that were overall satisﬁed to very satisﬁed with the MAL DL-PDT treatment were 80.4% and 90.3%, respectively. The vast
majorityofpatients (90.0%)wouldconsider usingMALDL-PDTagain if needed.Physician-assessedefﬁcacyat3 monthswasat least
much improved in83.5%ofpatients,with 45.9%ofpatients requiringno retreatment. RelatedAEswere reported in 15%ofpatients.
Conclusion Use of MAL DL-PDT for multiple face and/or scalp AKs resulted in high levels of patient and physician sat-
isfaction in clinical practice in Europe, reﬂecting the good efﬁcacy and high tolerability of this convenient procedure.
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Introduction
Prevalence rates of actinic keratosis (AK) in Europe are increas-
ing with the ageing population. A multicenter study across eight
European countries confirmed the importance of chronic and
high intermittent UV exposure, fair skin type and red or blonde
hair as important risk factors for AK.1
Although not all AKs will progress to invasive squamous cell
carcinoma (SCC) and some may regress, guidelines recommend
treating AK as they are recognized as precursors of invasive
SCC.2
Photodynamic therapy (PDT) is recommended as a first-line
treatment for individual (lesion-directed therapy) or multiple
and/or confluent AKs (field therapy) and has the potential to
delay/reduce the development of new lesions.2–4 Methyl
aminolevulinate (MAL) cream with red light (conventional
PDT; c-PDT) is indicated for the treatment of thin or non-
hyperkeratotic and non-pigmented AKs on the face and scalp,
superficial and/or nodular basal cell carcinoma and SCC in situ
(Bowen’s disease). More recently, MAL with daylight (MAL DL-
PDT) has shown good efficacy and safety in the treatment of face
and scalp, mild-to-moderate AK in multiple studies and has
been approved in many countries for this indication.5,6 In a ran-
domized, controlled trial in Europe, MAL DL-PDT demon-
strated similar efficacy, better tolerability with less pain and
resulted in higher subject satisfaction compared to MAL c-
PDT.6 Furthermore, a structured expert consensus statement on
AK recently rated MAL DL-PDT as the preferred option for
patients with multiple AKs on both small and large fields due to
its efficacy and tolerability profile.7
The objective of this study was to generate real-world data on
patient and physician satisfaction, as well as efficacy and safety,
of MAL DL-PDT in the treatment of face and scalp, mild-to-
moderate AK in Europe.
Methods
Study design
A prospective, multicenter, non-interventional study was con-
ducted in six European countries (Italy, Spain, France, the
Netherlands, Switzerland and the United Kingdom) at a total of
52 sites. Eligible patients were aged 18 years or older and had
been prescribed MAL DL-PDT as part of their routine medical
care to treat mild-to-moderate AK on the face and/or scalp.
The study was conducted in accordance with the Declaration
of Helsinki, the International Conference on Harmonization-
Good Clinical Practice principles and in compliance with local
regulatory requirements. The study was reviewed and approved
by the appropriate Independent Ethics Committees, and written
informed consent was obtained from all patients prior to study
initiation. The study is registered at ClinicalTrials.gov identifier
NCT02674048.
Treatment
A single treatment of MAL DL-PDT was administered
(Metvix/Metvixia, Galderma, Laboratories, Paris, France)
according to the local Summary of Product Characteristics.
Assessments
At baseline, the number and global severity of AK lesions
were assessed by the physician and a follow-up visit for
reassessment was proposed at 3 months. Efficacy was
assessed using a 6-point global improvement scale from 1
(clear) to 6 (worse). Patient-reported outcomes were assessed
by patient questionnaires at baseline and at 3 months. Each
physician completed a questionnaire when all their study
patients had completed the study. Post-treatment pain was
assessed after treatment administration on a numerical rating
scale (NRS) from 0 (no pain) to 10 (extreme pain). Inci-
dence and severity of adverse events (AE) were recorded at
each study visit.
Statistical methods
All collected variables were descriptively summarized without
replacement of any missing values (observed data only).
Results
Study population
Between April 2016 and August 2016, 325 patients were enrolled,
including 69 from Italy, 57 from Spain, 56 from France, 55 from
the Netherlands and 44 from each of Switzerland and the United
Kingdom. Overall, 314 (96.6%) attended a follow-up visit
3 months after treatment.
Most patients were elderly (mean age 74.1 years) men
(84.0%), and the majority had skin phototype II (68.0%)
(Table 1). Among the patients who had received previous treat-
ment for AK (88.9%), the mean duration of past AK treatments
was 7.2 years and 36.0% and 14.5% of patients had previously
received c-PDT and DL-PDT, respectively.
The majority of patients had multiple lesions (58.4% had >10
lesions) with most lesions located on the scalp (60.0%) and/or
forehead (54.2%) (Table 1). Patients had lesions of predomi-
nantly grade I (39.4%), grade II (33.2%) or a mix of grade I and
II (27.4%), and 10.5% of patients also had grade III AK
(Table 1).
All physicians (N = 52) were experienced dermatologists
with a mean of 20.4 years (min-max 9–33) in clinical prac-
tice, and they treated 26 AK patients per week on average
(min-max 30–100). The main reasons given by the physi-
cians for choosing MAL DL-PDT were the high number
and location of lesions over a large area to be treated, treat-
ment tolerability and efficacy and patient adherence (see
Table 2).
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MAL DL-PDT procedure
Before MAL application, the skin was prepared in most patients
(86.8%) and curettage (71.3%) was the most frequently used
method (Table 2). The entire field was prepared in around half
the patients (54.3%) and the lesions only in around half
(45.7%). The majority of patients applied sunscreen (83.1%),
mostly before skin preparation (72.6%).
MAL was applied on the entire field for most patients
(80.3%). After MAL application, patients went outside on
average 14.6 min later and stayed outside in the daylight for
2.0 h (Table 2).
Post-treatment care was recommended to the vast majority of
patients (98.5%), especially sunscreen application (92.5%)
(Table 2).
Efﬁcacy
In this patient population with multiple lesions, physician-
assessed efficacy at 3 months was at least much improved in
Table 1 Baseline demographic and clinical characteristics of the
study population
Patients, n (%)
N = 325
Age (years) Mean  SD 74.1  9.0
Min-max 41–95
Gender Male 273 (84.0%)
Skin phototype Type I 38 (11.7%)
Type II 221 (68.0%)
Type III 64 (19.7%)
Type IV 2 (0.6%)
Previous AK treatment
received
Yes 289 (88.9%)
Cryotherapy 233 (80.6%)
Conventional PDT 104 (36.0%)
Fluorouracil 61 (21.1%)
Diclofenac 56 (19.4%)
Ingenol mebutate 49 (17.0%)
Surgery 46 (15.9%)
Daylight PDT 42 (14.5%)
Imiquimod 37 (12.8%)
Laser 10 (3.5%)
Peelings 4 (1.4%)
Other 7 (2.4%)
Past medical history of
AK treatments (years),
N = 289
Mean  SD 7.2  5.9
Median (min-max) 5.0 (0–35)
Number of lesions <5 29 (8.9%)
5–10 106 (32.6%)
11–20 108 (33.2%)
>20 82 (25.2%)
Location of lesions Scalp 195 (60.0%)
Forehead 176 (54.2%)
Cheek 103 (31.7%)
Nose 84 (25.8%)
Full face 54 (16.6%)
Global severity of
the lesions
Majority of grade I 128 (39.4%)
Majority of grade II 108 (33.2%)
Well-balanced mix
of grade I and II
89 (27.4%)
Grade III lesions present Yes 34 (10.5%)
PDT, photodynamic therapy.
Table 2 Daylight-activated methyl aminolevulinate treatment pro-
cedure
Patients, n (%)
N = 325
Major consideration when choosing MAL DL-PDT treatment
Large area to treat 286 (88.0%)
High number of AK lesions 262 (80.6%)
Tolerability 260 (80.0%)
Location of lesions 244 (75.1%)
Efﬁcacy 236 (72.6%)
Maintenance of AK clearance 185 (56.9%)
Patient adherence 172 (52.9%)
Cosmetic beneﬁts 100 (30.8%)
Cost 26 (8.0%)
Preparation of skin before MAL application 282 (86.8%)
On entire ﬁeld 153 (54.3%)
Lesions only 129 (45.7%)
Method, N = 282
Curette 201 (71.3%)
Skin abrasive pad 51 (18.1%)
Keratolytic cream for a few days before 46 (16.3%)
Microdermabrasion 3 (1.1)
Other 6 (2.1%)
Sunscreen applied 270 (83.1%)
Before skin preparation and before MAL 196 (72.6%)
After skin preparation but before MAL 74 (27.4%)
Location of MAL application
On entire ﬁeld 261 (80.3%)
On lesions only 64 (19.7%)
Time between MAL application and daylight exposure (min), N = 168
Mean  SD 14.6  11
Median (min-max) 10 (0–60)
Time of daylight exposure (h), N = 168
Mean  SD 2.0  0.1
Median (min-max) 2.0 (1.5–3.0)
Total time of MAL exposure (h), N = 168
Mean  SD 2.4  0.3
Median (min-max) 2.3 (2–4.5)
Post-treatment care recommended 320 (98.5%)
Sunscreen 296 (92.5%)
Moisturizer 198 (61.9%)
Cleanser 164 (51.3%)
MAL DL-PDT, Daylight-activated methyl aminolevulinate.
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83.5% of patients with 45.9% of patients requiring no retreat-
ment at month 3. Of the patients (54.1%) requiring further
treatment at 3 months for residual lesions, the preferred treat-
ments were cryotherapy (55.3%) or MAL DL-PDT (21.2%).
Patient and physician satisfaction
At baseline after the MAL DL-PDT procedure, the vast majority
of subjects (94.0%) indicated that the procedure was convenient
to very convenient (Fig. 1).
At end of study, the proportion of patients and physicians
overall satisfied to very satisfied with the MAL DL-PDT treat-
ment was 80.4% and 90.3%, respectively. Most patients and
physicians were satisfied or very satisfied with the effectiveness
of the MAL DL-PDT treatment (78.9% and 82.6%, respectively)
and with the cosmetic appearance of the treated skin (76.9% and
98.1%, respectively) (Fig. 2a).
The vast majority of patients (90.0%) and physicians (98.1%)
would consider using MAL DL-PDT again (Fig. 2b).
Safety
After receiving the treatment, 66.2% of patients indicated they
were not bothered at all by pain (Fig. 3) and the mean pain level
was 1.4 (0–10 NRS scale).
Related AEs were reported in 14.8% of patients, but most
were mild in severity (10.8%).
The most commonly reported AEs were phototoxic AEs
including skin irritation (4.6%), skin burning sensation (3.7%)
and erythema (3.4%) (Table 3).
At the 3-month visit, 62.2% of patients indicated they were
not bothered at all by side-effects (Fig. 3) and the mean duration
of downtime due to skin reactions was 3.4  7.1 days. The vast
majority of physicians (86.5%) indicated they were very satisfied
with the tolerability of MAL DL-PDT (Fig. 4).
Discussion
In this population of patients, most of whom were na€ıve to MAL
DL-PDT (85.5%), high patient satisfaction (80.4% overall satis-
fied/very satisfied) was observed with this convenient (94.0%
found it to be convenient/very convenient), almost painless
procedure. Furthermore, despite the large number of lesions and
large areas treated, 83.5% of patients were at least much
improved at 3 months after a single treatment with MAL DL-
PDT, which may also have contributed to the high patient
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satisfaction. The overall patient satisfaction was similar to the
levels reported in a randomized controlled Phase III study con-
ducted in Europe (96.2% satisfied to very satisfied).6
The main reasons for prescribing MAL DL-PDT in these
patients were the large areas to be treated with many lesions, as
well as its good tolerability and efficacy. As the surrounding area
of sun-damaged skin (field cancerization) next to visible or pal-
pable AK lesions may contain subclinical lesions and cellular
changes, treatment of the entire field is important to treat both
subclinical lesions and visible AKs.8,9 In this study, MAL DL-
PDT was applied to the entire field in 80.3% of patients. Of
those patients (54.1%) requiring further treatment at 3 months
for residual lesions, the main treatments considered were
cryotherapy for residual individual lesions (55.3%) and around
one-fifth of patients (21.2%) received further treatment with
MAL DL-PDT.
Protocols for topical PDT conventionally recommend skin
preparation to remove scales and crusts in order to enhance
photosensitizing agent absorption and light penetration.2 Skin
preparation was performed over the entire field in half of the
cases (54.3% of patients), with curettage of individual lesions
(71.3%) much more commonly used than field skin prepara-
tions, such as skin abrasive pad or keratolytics (18.1% and
16.3%, respectively). More than one method could be used with,
for example, curettage of individual lesions combined with a
field skin preparation method.
Only 14.8% of patients had related AEs in this study, which is
much lower than the 45.4% reported in the randomized con-
trolled study conducted in Europe.6 The results presented here
for six European countries were part of a larger study, which also
included 81 Australian patients. In the Australian study, almost
half of the patients (48.1%) experienced related AEs, mainly
mild erythema.10 Phototoxic events are expected and appear to
have been under-reported in this European observational study,
possibly due to the fact that they were mild in severity and there
was no visit at week 1. Indeed, mild phototoxic events are not
necessarily considered as adverse events as photosensitivity from
PDT is a desirable, intrinsic reaction due to the treated area
being sensitized to light. By the 3-month visit, almost two-thirds
(62%) of patients indicated they had not been bothered at all by
side-effects and the average downtime of 3.4 days was consid-
ered acceptable.
Factors that may have contributed to the high patient and
physician satisfaction with MAL DL-PDT include the convenient
single treatment session (compared to several days for ingenol
mebutate to weeks for imiquimod and 5-fluorouracil, even
months with diclofenac plus hyaluronic acid gel).
A randomized, split-face, clinical trial on small areas of
25 cm2 harbouring a similar number of AKs, comparing a single
session of MAL DL-PDT with a 3-day treatment with ingenol
mebutate, demonstrated similar efficacy for both treatments on
face and scalp AKs.11 However, MAL DL-PDT was associated
with lower pain and inflammation scores, quicker wound heal-
ing, better cosmetic outcome and higher patient preference
(77% preferred MAL DL-PDT vs. 33% for ingenol mebutate).11
Similarly, in an intraindividual comparative analysis, MAL DL-
PDT showed similar effectiveness with a superior tolerability
profile in terms of local skin responses and pain compared to
ingenol mebutate.12 In an indirect comparison study in the
treatment of mild-to-moderate AK, MAL DL-PDT was more
than four times more effective than diclofenac plus hyaluronic
acid gel at 12 weeks.13
Limitations of this study are the non-interventional nature
and lack of a control group. However, this observational study
on a large sample size of patients (n = 325) and investigators
(n = 52) provided real-world evidence to support the results of
a previous randomized controlled trial conducted in Europe.6
Conclusions
Findings of this observational study in Europe are consistent
with those from previous trials and demonstrate high levels of
patient and physician satisfaction with MAL DL-PDT, reflecting
the good efficacy and high tolerability of this convenient proce-
dure in treating multiple mild-to-moderate AK of the face and/
or the scalp.
Table 3 Overall related adverse events during the treatment visit
and during the 3-month follow-up
Events Patients, n (%)
N = 325
Related adverse events 66 48 (14.8%)
Skin and subcutaneous tissue disorders 66 48 (14.8%)
Skin irritation 15 15 (4.6%)
Skin burning sensation 12 12 (3.7%)
Erythema 11 11 (3.4%)
Scab 10 10 (3.1%)
Pruritus 9 9 (2.8%)
Pain of skin 4 4 (1.2%)
Skin exfoliation 4 4 (1.2%)
Dermatitis 1 1 (0.3%)
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Figure 4 Physician satisfaction with the tolerability of daylight-
activated methyl aminolevulinate treatment.
© 2017 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology.
JEADV 2018, 32, 757–762
MAL DL-PDT use in Europe 761
Acknowledgments
The authors thank all the other investigators who contributed to
the study: JM Amici, P Beaulieu, H Garat, F Neuwirth, JL Ribou-
let, E Tisserand, G Toubel, P Young and P Zambelli from
France; G Argenziano, S Calvieri, SR Mercuri, S Piaserico, M
Puviani and M Venturini from Italy; A Avermaete, L Gonggryp,
W Habets, A Langeveld, T Smits, M Tjioe and L van der Spek
from the Netherlands; JL Artola Igarza, R Botella, J Dominguez,
V Garcia Patos, J Hernandez, R Ruız Villaverde and A Segurado
from Spain; O Gaide, A H€artel, L Imhof, P Itin, M Muhlstadt, S
Nobbe and NS Tomi from Switzerland: U Brudnik, M Kaur, S
Keohane, J Lear, C Morton, M Murison and C Perrett from the
United Kingdom. Editorial and medical writing assistance was
provided by Helen Simpson, PhD, of Galderma R&D.
References
1 Traianou A, Ulrich M, Apalla Z et al. EPIDERM Group. Risk factors for
actinic keratosis in eight European centres: a case-control study. Br J Der-
matol 2012; 167(Suppl 2): 36–42.
2 Morton C, Szeimies RM, Sidoroff A et al. European Dermatology Forum.
European Dermatology Forum Guidelines on topical photodynamic ther-
apy. Eur J Dermatol 2015; 25: 296–311.
3 Braathen LR, Szeimies RM, Basset-Seguin N et al. Guidelines on the use
of photodynamic therapy for nonmelanoma skin cancer: an international
consensus. J Am Acad Dermatol 2007; 56: 125–143.
4 Sidoroff A, Thaler P. Taking treatment decisions in non-melanoma skin
cancer-the place for topical photodynamic therapy (PDT). Photodiagnosis
Photodyn Ther 2010; 7: 24–32.
5 Rubel DM, Spelman L, Murrell DF et al. Daylight photodynamic therapy
with methyl aminolevulinate cream as a convenient, similarly effective,
nearly painless alternative to conventional photodynamic therapy in
actinic keratosis treatment: a randomized controlled trial. Br J Dermatol
2014; 171: 1164–1171.
6 Lacour JP, Ulrich C, Gilaberte Y et al. Daylight photodynamic therapy
with methyl aminolevulinate cream is effective and nearly painless in
treating actinic keratoses: a randomised, investigator-blinded, controlled,
phase III study throughout Europe. J Eur Acad Dermatol Venereol 2015;
29: 2342–2348.
7 Calzavara-Pinton P, Hædersdal M, Barber K et al. Structured expert con-
sensus on actinic keratosis: treatment algorithm focusing on daylight
PDT. J Cutan Med Surg 2017; 21(1S): 3S–16S.
8 Werner RN, Stockfleth E, Connolly SM et al. Evidence- and consensus-
based (S3) guidelines for the treatment of actinic keratosis – International
League of Dermatological Societies in cooperation with the European
Dermatology Forum – short version. J Eur Acad Dermatol Venereol 2015;
29: 2069–2079.
9 Szeimies RM, Atanasov P, Bissonnette R. Use of lesion response rate in
actinic keratosis trials. Dermatol Ther (Heidelb) 2016; 6: 461–464.
10 See JA, Gebauer K, Wu JK, Manoharan S, Kerrouche N, Sullivan J. High
Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate
Cream in the Treatment of Multiple Actinic Keratoses: Results of an
Observational Study in Australia. Dermatol Ther 2017; 7: 525–533.
11 Moggio E, Arisi M, Zane C, Calzavara-Pinton I, Calzavara-Pinton P. A
randomized split-face clinical trial analyzing daylight photodynamic ther-
apy with methyl aminolaevulinate vs ingenol mebutate gel for the treat-
ment of multiple actinic keratoses of the face and the scalp.
Photodiagnosis Photodyn Ther 2016; 16: 161–165.
12 Genovese G, Fai D, Fai C, Mavilia L, Mercuri SR. Daylight methyl-amino-
levulinate photodynamic therapy versus ingenol mebutate for the treat-
ment of actinic keratoses: an intraindividual comparative analysis.
Dermatol Ther 2016; 29: 191–196.
13 Calzavara-Pinton P, Zane C, Pacou M, Szeimies RM. Bucher’s indi-
rect comparison of daylight photodynamic therapy with methyl
aminolevulinate cream versus diclofenac plus hyaluronic acid gel for
the treatment of multiple actinic keratosis. Eur J Dermatol 2016; 26:
487–492.
© 2017 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology.
JEADV 2018, 32, 757–762
762 Fargnoli et al.
